Profile data is unavailable for this security.
About the company
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
- Revenue in USD (TTM)237.00m
- Net income in USD-231.00m
- Incorporated2015
- Employees577.00
- LocationArcus Biosciences Inc3928 Point Eden WayHAYWARD 94545-3719United StatesUSA
- Phone+1 (510) 694-6200
- Fax+1 (302) 730-1370
- Websitehttps://arcusbio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gyre Therapeutics Inc | 140.62m | -85.66m | 1.28bn | 593.00 | -- | 22.65 | -- | 9.13 | -1.88 | -1.88 | 1.55 | 0.663 | 2.00 | -- | 13.75 | 237,136.60 | -107.71 | -73.59 | -184.22 | -99.94 | 96.01 | -- | -53.91 | -205.62 | 2.97 | -- | 0.00 | -- | 14,188.41 | 616.69 | -1,027.55 | -- | 86.95 | -- |
Enliven Therapeutics Inc | 0.00 | -79.60m | 1.28bn | 46.00 | -- | 4.02 | -- | -- | -1.93 | -1.93 | 0.00 | 6.79 | 0.00 | -- | -- | 0.00 | -24.66 | -42.26 | -26.11 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
Prothena Corporation PLC | 89.25m | -172.40m | 1.31bn | 173.00 | -- | 2.61 | -- | 14.72 | -3.25 | -3.25 | 1.63 | 9.35 | 0.1308 | -- | -- | 515,901.70 | -25.26 | -14.20 | -27.09 | -15.11 | -- | -- | -193.17 | -111.02 | -- | -- | 0.00 | -- | 69.50 | 148.98 | -25.72 | -- | 9.71 | -- |
Ardelyx Inc | 159.11m | -65.81m | 1.31bn | 267.00 | -- | 8.71 | -- | 8.26 | -0.2883 | -0.2883 | 0.7007 | 0.6449 | 0.5689 | 3.20 | 7.90 | 595,917.60 | -23.53 | -46.14 | -29.95 | -57.32 | 85.30 | 88.15 | -41.36 | -240.87 | 4.36 | -9.86 | 0.3982 | -- | 138.61 | 116.66 | 1.70 | -- | 2.04 | -- |
Xencor Inc | 162.18m | -133.36m | 1.33bn | 280.00 | -- | 2.18 | -- | 8.23 | -2.19 | -2.19 | 2.68 | 9.94 | 0.1922 | -- | 11.02 | 579,217.90 | -15.90 | -3.70 | -17.39 | -4.12 | -- | -- | -82.74 | -15.92 | -- | -- | 0.0323 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
Disc Medicine Inc | 0.00 | -80.60m | 1.35bn | 74.00 | -- | 3.34 | -- | -- | -3.37 | -3.37 | 0.00 | 13.69 | 0.00 | -- | -- | 0.00 | -26.96 | -- | -28.13 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.22 | -- | -- | -- |
Day One Biopharmaceuticals Inc | 0.00 | -208.94m | 1.40bn | 174.00 | -- | 4.72 | -- | -- | -2.50 | -2.50 | 0.00 | 3.40 | 0.00 | -- | -- | 0.00 | -64.27 | -- | -69.93 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.87 | -- | -- | -- |
Nurix Therapeutics Inc | 62.30m | -165.00m | 1.41bn | 284.00 | -- | 3.81 | -- | 22.68 | -2.92 | -2.92 | 1.10 | 5.76 | 0.1446 | -- | -- | 219,376.80 | -38.30 | -33.01 | -46.57 | -39.66 | -- | -- | -264.84 | -260.65 | -- | -- | 0.00 | -- | 99.31 | 15.50 | 20.19 | -- | 39.42 | -- |
Sana Biotechnology Inc | 0.00 | -308.61m | 1.42bn | 328.00 | -- | 3.78 | -- | -- | -1.53 | -1.53 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -43.21 | -38.99 | -48.50 | -42.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.11 | -- | 112.71 | -- |
Arcus Biosciences Inc | 237.00m | -231.00m | 1.44bn | 577.00 | -- | 2.03 | -- | 6.07 | -3.10 | -3.10 | 3.07 | 7.78 | 0.1861 | -- | 6.24 | 410,745.20 | -18.14 | -15.85 | -21.35 | -18.25 | -- | -- | -97.47 | -103.46 | -- | -- | 0.00 | -- | 4.46 | 69.54 | -14.98 | -- | 45.01 | -- |
Longboard Pharmaceuticals Inc | 0.00 | -57.95m | 1.45bn | 50.00 | -- | 4.64 | -- | -- | -2.25 | -2.25 | 0.00 | 8.07 | 0.00 | -- | -- | 0.00 | -28.45 | -- | -29.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.84 | -- | -- | -- |
Vir Biotechnology Inc | 79.60m | -539.44m | 1.46bn | 587.00 | -- | 0.9394 | -- | 18.29 | -4.01 | -4.01 | 0.5916 | 11.39 | 0.0357 | -- | -- | 135,603.10 | -24.19 | -0.6081 | -27.80 | -0.7192 | 98.85 | -- | -677.69 | -1.53 | -- | -- | 0.00 | -- | -94.67 | 51.87 | -219.24 | -- | 16.77 | -- |
Belite Bio Inc (ADR) | 0.00 | -32.61m | 1.49bn | 20.00 | -- | 15.18 | -- | -- | -1.18 | -1.18 | 0.00 | 3.24 | 0.00 | -- | -- | 0.00 | -46.26 | -- | -46.26 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -150.09 | -- | -- | -- |
Dynavax Technologies Corp | 236.15m | 9.22m | 1.52bn | 408.00 | 232.43 | 2.46 | 111.13 | 6.44 | 0.05 | 0.05 | 1.67 | 4.73 | 0.2414 | 0.7769 | 3.24 | 578,796.60 | 0.9427 | 4.16 | 1.02 | 5.71 | 80.34 | 64.83 | 3.91 | 9.19 | 14.10 | -- | 0.265 | 0.00 | -67.86 | 95.19 | -102.18 | -- | -23.03 | -- |
MannKind Corp | 224.60m | 8.49m | 1.59bn | 414.00 | 249.68 | -- | 118.44 | 7.09 | 0.0234 | 0.0234 | 0.7589 | -0.8492 | 0.5766 | 2.69 | 11.34 | 542,509.70 | 2.18 | -26.07 | 2.84 | -37.80 | 70.99 | 59.68 | 3.78 | -57.61 | 3.57 | 1.50 | 1.80 | -- | 99.42 | 48.17 | 86.34 | -- | 160.47 | -- |
Spyre Therapeutics Inc | 688.00k | -364.23m | 1.60bn | 30.00 | -- | -- | -- | 2,322.85 | -71.35 | -71.35 | 0.0456 | 11.08 | 0.0026 | -- | -- | 22,933.33 | -134.88 | -101.87 | -150.32 | -118.83 | -- | -- | -52,939.68 | -2,949.59 | -- | -- | 0.00 | -- | -61.96 | -25.61 | -304.21 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 31 Mar 2024 | 8.65m | 9.51% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 4.90m | 5.39% |
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 4.78m | 5.26% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 4.69m | 5.15% |
Woodline Partners LPas of 31 Mar 2024 | 2.88m | 3.17% |
Point72 Asset Management LPas of 31 Mar 2024 | 1.91m | 2.11% |
Dimensional Fund Advisors LPas of 31 Mar 2024 | 1.48m | 1.63% |
Geode Capital Management LLCas of 31 Mar 2024 | 1.17m | 1.29% |
AllianceBernstein LPas of 31 Mar 2024 | 1.15m | 1.27% |
Threadneedle Asset Management Ltd.as of 31 Mar 2024 | 1.04m | 1.14% |